US Pharma MarketingJazz turns to AbCellera for T cell engagers in GI cancers in up to $4.1B partnership
AbCellera and Jazz Pharmaceuticals strike a preclinical T cell engager deal worth up to $4.1B targeting gastrointestinal and other solid tumor cancers across up to five programs. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR…
For much of its first decade, Canadian antibody developer AbCellera signed partnership after partnership, securing 40 biopharma alliances that led to more than a dozen clinical-stage drug candidates.
Then, in 2023 ...
Source: Endpoints News